Sanofi-Aventis Study Sees Significant A1c Reductions with Lantus and Apidra Compared to Pre-mixed Insulin for Type 2s
This press release is an announcement submitted by Sanofi-aventis, and was not written by Diabetes Health.
At the recent 44th annual meeting of the European Association for the Study of Diabetes (EASD), sanofi-aventis announced a study demonstrating that a basal-bolus insulin regimen with Lantus® once daily (basal insulin) and rapid-acting Apidra® (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) resulted in significant A1c reductions from baseline as compared to pre-mixed insulin in people with type 2 diabetes.
In the GINGER study, the overall A1c change from baseline to endpoint with Lantus and Apidra was 1.3% versus 0.8% with pre-mix. The number of patients who reached an A1c of less than 7.0% at endpoint was significantly higher with Lantus and Apidra when compared to pre-mixed insulin.
Source: Sanofi-aventisClick Here To View Or Post Comments